Finzati - Logo
MRK logo

Merck & Co., Inc.

MRK • Drug Manufacturers - General
$148.09
▲ +4.46 (+3.11%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHLY FAVORABLE PROFILEExcellentConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$359.08B
Growth
7.6%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 28.1%Positive revenue growth · 7.8%Positive free cash flow · 4.94Consistent free cash flow · 5/5Reasonable earnings multiple · 14.43
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: Apr 30, 2026, 12:00 AM UTCLast profile update: Aug 6, 2026, 1:22 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$148.09
Change3.11%
Shares Out2.47B
Market Cap$359.08B
Enterprise Value$402.50B
52W Range77.58 - 135.05
Beta0.21
P/E40.19
P/S5.47
P/B7.83
P/FCF25.44
EV/Sales6.14

Investment DNA

How strong this company looks for long-term investors

85
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
81/100
Growth Potential
Revenue and expansion
80/100
Price Attractiveness
Cheap or expensive today
73/100
Why this score▼
Stable or improving margins · 28.1%Positive revenue growth · 7.8%Positive free cash flow · 4.94Consistent free cash flow · 5/5Reasonable earnings multiple · 14.43Healthy liquidity · 1.54

Analyst view

Analyst sentiment and price target

MRK
Analyst sentiment
Based on 38 analyst votes · 2026-10-20
83/100
Bullish
Bullish
26
Hold
11
Bearish
1
Price Target
2026-08-05
Low
$105.00
Mean
$140.18
Median
$145.00
High
$155.00

Company Overview

IPO: 1/13/1978
Industry: Drug Manufacturers - General
P/B i: 7.83
Debt / Equity i: 0.96
Operating Margin: 36.17%
Net Margin: 28.12%
ROE i: -
ROIC: -

Financial Health

Score16 / 20
Debt / Equity: 0.96
Current Ratio: 1.54
Quick Ratio: 1.30
Status: Strong

Insider Transactions

Recent executive and insider activity

Coe Mary Ellen
Transaction: 06/30/2026
BUY
Change
—
Price
Not reported
Filing
07/01/2026
Type
BUY
Karsanbhai Surendralal Lanca
Transaction: 06/30/2026
BUY
Change
—
Price
Not reported
Filing
07/01/2026
Type
BUY
Seidman Christine E
Transaction: 06/30/2026
BUY
Change
—
Price
Not reported
Filing
07/01/2026
Type
BUY